Clinical Trials Browser

Phase 1/2 × INDUSTRY × Immune Checkpoint Inhibitors × Clear all

NCT06710847 2026-02-02

SYLVER

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03425279 2025-09-23

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Phase 1/2 Completed

Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT05497453 2025-02-03

MYCHELANGELO I

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03504488 2025-01-15

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Phase 1/2 Completed

BreastDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Phase 1/2 Completed

40 enrolled 16 charts

Other solid neoplasm

Solid Tumor, Adult

NCT04721223 2024-09-19

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms